Journal of Bacteriology & Parasitology

Novel Approach and Technologies in Treating Bacterial Infections

Vozza Lorena Eugenia^* Department of Biology, National University of Mar del Plata, Mar del Plata, Argentina
^*Correspondence: Vozza Lorena Eugenia, Department of Biology, National University of Mar del Plata, Mar del Plata, Argentina, Email:

Received: 18-Aug-2023, Manuscript No. JBP-23-23366; Editor assigned: 21-Aug-2023, Pre QC No. JBP-23-23366 (PQ); Reviewed: 04-Sep-2023, QC No. JBP-23-23366; Revised: 11-Sep-2023, Manuscript No. JBP-23-23366 (R); Published: 18-Sep-2023, DOI: 10.35248/2155-9597.23.14.483

Description

In recent decades, the emergence and spread of antibioticresistant bacteria have become a global health crisis. Traditional antibiotics, once addressed as phenomenon drugs, are increasingly losing their efficacy due to the development of resistance mechanisms by bacteria. This related pattern has prompted researchers and healthcare professionals to seek new approaches for treating bacterial infections that are resistant to antibiotics. In this article, we will explore some innovative strategies and technologies that are revolutionizing the field of infectious disease treatment.

One main approach to combat antibiotic-resistant bacteria is phage therapy. Phage therapy involves isolating and using these viruses to target and destroy pathogenic bacteria. Unlike antibiotics, which are broad-spectrum and can harm beneficial bacteria, phages are highly specific, targeting only the bacteria responsible for the infection. This specificity reduces the risk of collateral damage to the patient's microbiome [1-3].

Phage therapy has shown remarkable success in treating bacterial infections that are resistant to antibiotics. It has been particularly effective against multidrug-resistant bacteria, such as those belonging to the genus Acinetobacter or Pseudomonas. While phage therapy is not a new concept, recent advances in genomics and biotechnology have made it more accessible and personalized to individual infections. Researchers can now select phages with precision, increasing the likelihood of successful treatment. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated systems have revolutionized genetic engineering and are now being explored as a tool to combat antibiotic resistance. Researchers are developing CRISPR-Cas-based approaches to target and disrupt genes responsible for antibiotic resistance in bacteria [4-7].

One such approach is known as CRISPR-Cas antimicrobials. These are designed to specifically target and cleave the DNA sequences responsible for antibiotic resistance, effectively rendering the bacteria sensitive to antibiotics once again. This technique holds great in re-sensitizing bacteria to existing antibiotics, potentially extending the lifespan of these drugs.

Another strategy in the fight against antibiotic-resistant bacteria is the use of combination therapy. Rather than relying on a single antibiotic, which bacteria can develop resistance to, combination therapy involves using two or more antibiotics with different mechanisms of action. This multi-pronged approach makes it significantly more difficult for bacteria to develop resistance since they would need to simultaneously evolve resistance to multiple drugs. In some cases, combining antibiotics can also enhance their individual effectiveness. For example, the combination of trimethoprim and sulfamethoxazole is commonly used to treat urinary tract infections because these drugs inhibit different steps in the same metabolic pathway, leading to a synergistic effect [8].

Nanotechnology has provided new opportunities for treating antibiotic-resistant bacterial infections. Nanoparticles, which are tiny structures at the nanoscale, can be engineered to deliver antibiotics directly to the site of infection. This targeted delivery reduces the amount of antibiotic needed and minimizes the impact on the patient's overall microbiome. Nanoparticles can be functionalized to interact with bacterial cell walls or membranes, increasing the efficiency of antibiotic delivery. Researchers are also exploring the use of nanoparticles as carriers for novel antimicrobial agents, such as peptides and enzymes, which can combat antibiotic-resistant bacteria through alternative mechanisms [9].

The human immune system is a powerful weapon against bacterial infections, and researchers are finding ways to enhance its natural abilities. Immunotherapy involves using antibodies, cytokines, or other immune system modulators to boost the body's defenses against bacterial pathogens. Monoclonal antibodies, for example, can be engineered to target specific bacterial proteins or toxins. By neutralizing these components, the antibodies can effectively disarm the bacteria and aid in their clearance by the immune system. This approach has shown in treating infections caused by bacteria like Staphylococcus aureu.

New approaches are essential, it's equally important to preserve the efficacy of existing antibiotics. Antibiotic stewardship programs aim to promote the responsible use of antibiotics in both clinical and agricultural settings. These programs educate healthcare providers and patients about proper antibiotic use, emphasizing the importance of completing prescribed courses of antibiotics and avoiding unnecessary antibiotic use. In agriculture, antibiotic stewardship focuses on reducing the use of antibiotics in livestock farming, which contributes to the development of antibiotic-resistant bacteria. Regulations and incentives are being implemented to encourage more responsible antibiotic use in the agricultural industry [10].

Conclusion

Innovative approaches such as phage therapy, CRISPR-Cas gene editing, combination therapy, nanotechnology, immunotherapy, and the use of antibiotics are providing an alternative to fight against drug-resistant infections. These approaches not only hold for treating existing infections but also for preventing the emergence of further antibiotic resistance. As we continue to explore and refine these strategies, we move closer to a future where bacterial infections resistant to antibiotics may no longer pose the same level of threat to public health.

References

1. Taylor PW, Stapleton PD, Luzio JP. New ways to treat bacterial infections. Drug Discov Today. 2002;7(21):1086-1091.

   [Crossref] [Google Scholar] [PubMed]

2. Fernebro J. Fighting bacterial infections-future treatment options. Drug Resist Updat. 2011;14(2):125-139.

   [Crossref] [Google Scholar] [PubMed]

3. Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am. 2004;51(4):939-959.

   [Crossref] [Google Scholar] [PubMed]

4. Del Pozo JL, Patel R. The challenge of treating biofilm‐associated bacterial infections. Clin Pharmacol Ther. 2007;82(2):204-209.

   [Crossref] [Google Scholar] [PubMed]

5. Keating GM. Sitafloxacin: In bacterial infections. Drugs. 2011;71:731-744.

   [Crossref] [Google Scholar] [PubMed]

6. Parsonnet J. Bacterial infection as a cause of cancer. Environ Health Perspect. 1995;103(suppl 8):263-268.

   [Crossref] [Google Scholar] [PubMed]

7. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310-1324.

   [Crossref] [Google Scholar] [PubMed]

8. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56:S1-S12.

   [Crossref] [Google Scholar] [PubMed]

9. Gao W, Thamphiwatana S, Angsantikul P, Zhang L. Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(6):532-547.

   [Crossref] [Google Scholar] [PubMed]

10. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008;21(2):122-128.

    [Crossref] [Google Scholar] [PubMed]